Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Official Sees More “Specified Clinical Research” Data Used in Regulatory Submissions to Fill Industry-Academia Void
July 20, 2022
- PMDA Head Fujiwara Re-Elected as ICMRA Vice Chair
July 20, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Up for MHLW Panel Review on July 29
July 19, 2022
- Japan Panel to Discuss 4th COVID Shot to Healthcare Providers: Health Minister
July 19, 2022
- MHLW Eyes Expert Panel Launch This Summer for Drug Distribution and Pricing: Official
July 19, 2022
- Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
- MHLW Mulls Data Collection Policy for Conditionally Approved MSC Therapies
July 14, 2022
- Shionogi’s COVID-19 Pill Up for Expert Redeliberation on July 20
July 14, 2022
- Govt Council Calls for Steps to Beef Up Japan’s Clinical Trial System for Vaccines
July 13, 2022
- Accelerate Social Implementation of Genomic Medicine: Study Group
July 13, 2022
- 92 Defects/Health Damages Reported for Kymriah in October-March
July 13, 2022
- All 10 Pharma-Backed Candidates Grab Upper House Seats
July 12, 2022
- Japan Detects 4 More Probable Cases of Pediatric Hepatitis
July 11, 2022
- After Abe’s Death, Pharma and Medical Circles Fret Shift to Austerity and Tougher Drug Pricing
July 11, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
July 11, 2022
- Label Revision Ordered for Novavax Jab to Add Myocarditis Risks
July 11, 2022
- Drug Makers Can Now Access MID-NET from Their Own Offices
July 11, 2022
- Japan to Discuss Fourth COVID Shot for Below Age 60: Govt Official
July 8, 2022
- Panel Designates COVID, Monkeypox and Other Priority Infectious Diseases for SCARDA Funding
July 8, 2022
- All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…